Skip to main content
. 2022 Sep 8;7(17):e161045. doi: 10.1172/jci.insight.161045

Figure 4. CD161-expressing T cell levels are associated with a higher SARS-CoV-2 vaccine T cell response.

Figure 4

(A) Dot plots representing the percentage of memory and CM CD4+ T cells expressing CD161 in > 60-year-old (red) and < 60-year-old (blue) participants before SARS-CoV-2 vaccination (PRE), 3 weeks after the first dose (1D), and 2 months after the second dose (2D) (right). Pseudocolor dot plot graphs show representative data of memory CD4+ T cells from a > 60-year-old and < 60-year-old donor expressing CD161 before vaccination (left). (B) Correlation matrix representing associations of the percentage of CD161+ T cells before vaccination with SARS-CoV-2 S–specific CD4+ and CD8+ T cells expressing IFN-γ or cytotoxicity markers 2 months after the second dose of vaccination in all participants. Mann-Whitney U (A), Wilcoxon (A), and Spearman (B) tests were used (n = 32). Friedman test was applied in A (Memory CD4+ T cells: > 60-year-old, P = 0.091, and < 60-year-old, P = 0.368; CM CD4+ T cells: > 60-year-old, P = 0.159, and < 60-year-old, P = 0.549).